<div class="row">
    <div class="col">
        <p>A Summary of Findings (SoF) table is designed to summarize the key results of a pairwise meta-analysis and to evaluate your confidence in the estimates of effect. The table summarizes the results for patient important outcomes for patients receiving direct acting anti-coagulant (DOACs) as compared to low molecular weight heparin (LMWH).</p>
    </div>
</div>
<table class="sof-table">
    <tr>
        <td colspan="7" class="dk fw-b">Certainty assessment</td>
        <td colspan="2" class="dk fw-b">No of patients</td>
        <td colspan="2" class="dk fw-b">Effect</td>
        <td rowspan="2" class="dk fw-b">Certainty</td>
    </tr>
    <tr>
        <td class="dk fw-b">No of studies</td>
        <td class="dk fw-b">Study design</td>
        <td class="dk fw-b">Risk of bias</td>
        <td class="dk fw-b">Inconsistency</td>
        <td class="dk fw-b">Indirectness</td>
        <td class="dk fw-b">Imprecision</td>
        <td class="dk fw-b">Other<br>considerations</td>
        <td class="dk fw-b">DOACs</td>
        <td class="dk fw-b">LMWH<br>(Dalteparin)</td>
        <td class="dk fw-b">Relative<br>
            (95% CI)
            </td>
        <td class="dk fw-b">Absolute<br>
            (95% CI)
            </td>
    </tr>

    <tr><td colspan="12" class="ta-l ti-1 fw-b hd">
        Venous thromboembolism recurrence
    </td></tr>
    <tr>
        <td>4</td>
        <td>randomised trials</td>
        <td>not serious </td>
        <td>not serious </td>
        <td>not serious </td>
        <td>not serious </td>
        <td>none</td>
        <td>82/1446<br> (5.7%) </td>
        <td>132/1448<br> (9.1%) </td>
        <td><b>OR 0.59</b><br>
            (0.41 to 0.86)  </td>
        <td><b>35 fewer per 1,000</b><br>
            (from 52 fewer to 12 fewer)  </td>
        <td class="ta-l ti-1">
            <i class="sof-sym sof-sym-b"></i>
            <i class="sof-sym sof-sym-b"></i>
            <i class="sof-sym sof-sym-b"></i>
            <i class="sof-sym sof-sym-b"></i> HIGH</td>
        
    </tr>

    <tr><td colspan="12" class="ta-l ti-1 fw-b hd">
        Major bleeding
    </td></tr>
    <tr>
        <td>4</td>
        <td>randomised trials</td>
        <td>not serious </td>
        <td>not serious </td>
        <td>not serious </td>
        <td>very serious <sup>a</sup> </td>
        <td>none</td>
        <td>69/1446<br> (4.8%) </td>
        <td>53/1448<br> (3.6%) </td>
        <td><b>OR 1.34</b><br>
            (0.83 to 2.18)  </td>
        <td><b>12 more per 1,000</b><br>
            (from 6 fewer to 39 more) 
             </td>
        <td class="ta-l ti-1">
            <i class="sof-sym sof-sym-b"></i>
            <i class="sof-sym sof-sym-b"></i>
            <i class="sof-sym sof-sym-w"></i>
            <i class="sof-sym sof-sym-w"></i> LOW</td>
        
    </tr>

    <tr><td colspan="12" class="ta-l ti-1 fw-b hd">
        Clinically relevant non-major bleeding
    </td></tr>
    <tr>
        <td>4</td>
        <td>randomised trials</td>
        <td>not serious </td>
        <td>not serious </td>
        <td>not serious </td>
        <td>serious <sup>b</sup></td>
        <td>none</td>
        <td>162/1446<br> (11.2%) </td>
        <td>107/1448<br> (7.4%) </td>
        <td><b>OR 1.65</b><br>
            (1.13 to 2.42) 
            </td>
        <td><b>42 more per 1,000</b><br>
            (from 9 more to 88 more)             
             </td>
        <td class="ta-l ti-1">
            <i class="sof-sym sof-sym-b"></i>
            <i class="sof-sym sof-sym-b"></i>
            <i class="sof-sym sof-sym-b"></i>
            <i class="sof-sym sof-sym-w"></i> MODERATE </td>
        
    </tr>

    <tr><td colspan="12" class="ta-l ti-1 fw-b hd">
        Composite of VTE recurrence and major bleeding (net clinical benefit)
    </td></tr>
    <tr>
        <td>4</td>
        <td>randomised trials</td>
        <td>not serious </td>
        <td>not serious </td>
        <td>not serious </td>
        <td>very serious <sup>a</sup></td>
        <td>none</td>
        <td>151/1446 <br>(10.4%) </td>
        <td>184/1448 <br>(12.7%) </td>
        <td><b>OR 0.78</b><br>
            (0.53 to 1.14) 
            </td>
        <td><b>25 fewer per 1,000</b><br>
            (from 55 fewer to 15 more) 
            </td>
        <td class="ta-l ti-1">
            <i class="sof-sym sof-sym-b"></i>
            <i class="sof-sym sof-sym-b"></i>
            <i class="sof-sym sof-sym-w"></i>
            <i class="sof-sym sof-sym-w"></i> LOW  </td>
        
    </tr>

    <tr><td colspan="12" class="ta-l ti-1 fw-b hd">
        Mortality
    </td></tr>
    <tr>
        <td>4</td>
        <td>randomised trials</td>
        <td>not serious </td>
        <td>not serious </td>
        <td>not serious </td>
        <td>very serious <sup>a</sup></td>
        <td>none</td>
        <td>412/1446<br> (28.5%) </td>
        <td>416/1448<br> (28.7%) </td>
        <td><b>OR 0.99</b><br>
            (0.79 to 1.24) 
            </td>
        <td><b>2 fewer per 1,000</b><br>
            (from 46 fewer to 46 more) 
            </td>
        <td class="ta-l ti-1">
            <i class="sof-sym sof-sym-b"></i>
            <i class="sof-sym sof-sym-b"></i>
            <i class="sof-sym sof-sym-w"></i>
            <i class="sof-sym sof-sym-w"></i> LOW  </td>
        
    </tr>

    <tr><td colspan="12" class="ta-l ti-1 fw-b hd">
        Major gastrointestinal bleeding
    </td></tr>
    <tr>
        <td>3</td>
        <td>randomised trials</td>
        <td>not serious </td>
        <td>not serious </td>
        <td>not serious </td>
        <td>very serious <sup>a</sup></td>
        <td>none</td>
        <td>39/1301<br>(3.0%) </td>
        <td>20/1306 <br>(1.5%) </td>
        <td><b>OR 1.94</b><br>
            (0.96 to 3.95) 
            </td>
        <td><b>14 more per 1,000</b><br>
            (from 1 fewer to 43 more) 
            </td>
        <td class="ta-l ti-1">
            <i class="sof-sym sof-sym-b"></i>
            <i class="sof-sym sof-sym-w"></i>
            <i class="sof-sym sof-sym-w"></i>
            <i class="sof-sym sof-sym-w"></i> VERY LOW  </td>
        
    </tr>

    <tr><td colspan="12" class="ta-l ti-1 fw-b hd">
        Major genitourinary bleeding
    </td></tr>
    <tr>
        <td>3</td>
        <td>randomised trials</td>
        <td>not serious </td>
        <td>not serious </td>
        <td>not serious </td>
        <td>very serious <sup>a</sup></td>
        <td>none</td>
        <td>10/1301<br>(0.8%) </td>
        <td>1/1306<br>(0.1%) </td>
        <td><b>OR 5.03</b><br>
            (1.08 to 23.34) 
            </td>
        <td><b>3 more per 1,000</b><br>
            (from 0 fewer to 17 more) 
            </td>
        <td class="ta-l ti-1">
            <i class="sof-sym sof-sym-b"></i>
            <i class="sof-sym sof-sym-b"></i>
            <i class="sof-sym sof-sym-w"></i>
            <i class="sof-sym sof-sym-w"></i> LOW  </td>
        
    </tr>

    <tr><td colspan="12" class="ta-l ti-1 fw-b hd">
        Fatal bleeding
    </td></tr>
    <tr>
        <td>2</td>
        <td>randomised trials</td>
        <td>not serious </td>
        <td>not serious </td>
        <td>not serious </td>
        <td>very serious <sup>a</sup></td>
        <td>none</td>
        <td>0/1098<br>(0.0%) </td>
        <td>4/1103<br>(0.4%) </td>
        <td><b>OR 0.20</b><br>
            (0.02 to 1.72) 
            </td>
        <td><b>3 fewer per 1,000</b><br>
            (from 4 fewer to 3 more) 
            </td>
        <td class="ta-l ti-1">
            <i class="sof-sym sof-sym-b"></i>
            <i class="sof-sym sof-sym-w"></i>
            <i class="sof-sym sof-sym-w"></i>
            <i class="sof-sym sof-sym-w"></i> VERY LOW  </td>
        
    </tr>

    <tr><td colspan="12" class="ta-l ti-1 fw-b hd">
        Intracranial bleeding
    </td></tr>
    <tr>
        <td>2</td>
        <td>randomised trials</td>
        <td>not serious </td>
        <td>not serious </td>
        <td>not serious </td>
        <td>very serious <sup>a</sup></td>
        <td>none</td>
        <td>2/1098<br>(0.2%) </td>
        <td>6/1103<br>(0.5%) </td>
        <td><b>OR 0.40</b><br>
            (0.09 to 1.77) 
            </td>
        <td><b>3 fewer per 1,000</b><br>
            (from 5 fewer to 4 more)
            </td>
        <td class="ta-l ti-1">
            <i class="sof-sym sof-sym-b"></i>
            <i class="sof-sym sof-sym-w"></i>
            <i class="sof-sym sof-sym-w"></i>
            <i class="sof-sym sof-sym-w"></i> VERY LOW  </td>
        
    </tr>
</table>
<p class="sof-table-note">CI: Confidence interval; OR: Odds ratio</p>
<p class="sof-table-note" style="font-size: 13px;"><b>Explanations</b></p>
<p class="sof-table-note"><sup>a.</sup> Serious imprecision due to wide confidence intervals which include clinically meaningful benefit and harm </p>
<p class="sof-table-note"><sup>b.</sup> Serious imprecision due to wide confidence intervals </p>
<p class="sof-table-note"><sup>c.</sup> Very serious imprecision due to very wide confidence intervals which include clinically meaningful benefit and harm</p>
<p class="sof-table-note"><sup>d.</sup> Very serious imprecision due to very wide confidence intervals </p>
